• Pazopanib Hydrochloride: Strategic Horizons in Translational

  2026-07-13

  This thought-leadership article explores the mechanistic foundations and translational opportunities of Pazopanib Hydrochloride (GW786034) as a multi-target receptor tyrosine kinase inhibitor. Integrating insights from in vitro drug response methodologies, competitive benchmarking, and translational frameworks, it provides actionable guidance for researchers aiming to elevate anti-angiogenic cancer studies. The discussion uniquely bridges rigorous protocol recommendations with a forward-looking vision, positioning APExBIO as a partner in next-generation oncology research.

• Proteasome Heterogeneity and Subtype Markers in Breast Cance

  2026-07-13

  This study systematically characterizes the diversity of proteasome composition and activity across molecular subtypes of breast cancer, revealing strong correlations with key diagnostic markers. The findings offer a mechanistic rationale for developing proteasome-targeted therapies optimized to tumor subtype.

• CYR61-Mediated Migrasome Signaling Restores Osteogenesis in

  2026-07-12

  This study uncovers how the ECM protein CYR61, delivered via migrasomes, promotes migration and osteoblastic differentiation in irradiated bone marrow mesenchymal stem cells (IR BMSCs). The findings suggest a new therapeutic angle for osteoradionecrosis of the jaw (ORNJ), highlighting the mechanistic importance of migrasome-mediated protein transfer and integrin signaling.

• Polymyxin B Sulfate: Advanced Workflows for MDR Infection Re

  2026-07-10

  Polymyxin B sulfate empowers infection researchers with dual bactericidal and immunomodulatory action, enabling robust models for multidrug-resistant Gram-negative bacteria. This guide delivers actionable protocols, troubleshooting insights, and translational strategies to elevate experimental rigor—anchored by the latest evidence and APExBIO’s trusted quality.

• Optimizing Immunoassays with c-Myc tag Peptide (SKU A6003)

  2026-07-09

  This article addresses real-world laboratory challenges in immunoassays and transcription factor studies, demonstrating how the c-Myc tag Peptide (SKU A6003) ensures reliable displacement of c-Myc-tagged fusion proteins and reproducible assay results. Researchers will find scenario-driven guidance, protocol parameters, and evidence-based recommendations grounded in published literature and product data.

• YM 58483 (BTP2): Selective SOCE Blocker for Fibrosis Researc

  2026-07-09

  YM 58483 (BTP2) is a potent, selective inhibitor of store-operated Ca2+ entry (SOCE), widely used in immune modulation and fibrosis research. It blocks CRAC and TRP channels, suppressing T cell activation and fibrogenic signaling. Recent evidence supports its efficacy in models of postirradiation salivary gland fibrosis.

• Low-Affinity N-Type Ca Channel Blockade by v-Agatoxin-IVA: I

  2026-07-08

  Sidach and Mintz's study re-examines the pharmacological selectivity of the spider toxin v-agatoxin-IVA (v-Aga-IVA) on neuronal calcium channel subtypes. Their work demonstrates that while v-Aga-IVA is a potent and selective blocker of P-type calcium channels, it also exhibits low-affinity inhibition of N-type channels at higher concentrations, challenging prior assumptions about its specificity and impacting experimental design in calcium channel research.

• Ranolazine: Anti-Ischemic Agent for Cardiac and Metabolic Re

  2026-07-08

  Ranolazine is a high-purity anti-ischemic agent that inhibits late sodium current in cardiac cells and enhances glucose oxidation, reducing ischemic injury. It is widely used in myocardial relaxation studies and cardiac ischemia research due to its dual action on electrophysiology and metabolism. APExBIO supplies Ranolazine (A8510) with documented stability and purity for research workflows.

• Morin as a Mechanistic Probe: Beyond Antioxidant to Metaboli

  2026-07-07

  Explore Morin's role as a mechanistic probe in metabolic research, with a focus on its unique inhibition of adenosine 5′-monophosphate deaminase. This article offers advanced insights into Morin’s biochemical applications and assay design, setting it apart from other natural flavonoids.

• PFHxS-Induced Hepatotoxicity via PPARα in Zebrafish Models

  2026-07-07

  This study investigates how environmentally relevant concentrations of perfluorohexanesulfonic acid (PFHxS), a widely detected short-chain PFAS, induce hepatotoxicity in larval zebrafish by activating the PPARα signaling pathway. The research employs integrated transcriptomic and biochemical analyses, and demonstrates that PPARα antagonism can mitigate PFHxS-induced liver toxicity, providing mechanistic insights for metabolic disease modeling.

• KG-501: Applied Workflows for Transcriptional Coactivator Di

  2026-07-06

  KG-501 enables precise disruption of CREB-mediated transcription and Myb-KIX domain interactions, empowering targeted modulation of gene expression in cancer and immune models. Explore practical workflows, troubleshooting strategies, and pivotal insights from the latest colitis-associated cancer research that showcase KG-501’s unique utility as an epigenetic regulation modulator.

• Fluoroalkane-Modified Polymers Advance Personalized mRNA Vac

  2026-07-06

  This study introduces fluoroalkane-grafted cationic polymers (F-PEI) as efficient, adjuvant-free carriers for mRNA-based personalized cancer vaccines. Their unique properties enhance mRNA delivery, antigen presentation, and anti-tumor immune responses, representing a promising alternative to lipid nanoparticles in mRNA therapeutics.

• Prochlorperazine-Induced Neuroleptic Malignant Syndrome: Cas

  2026-07-05

  This article examines a recent case report detailing neuroleptic malignant syndrome (NMS) triggered by prochlorperazine in an elderly patient, with a focus on diagnostic challenges, clinical features, and effective management strategies. Findings emphasize the necessity of early recognition and tailored treatment for NMS, even when standard laboratory markers are absent.

• LMP2A-mTORC1-GCNT3 Axis Drives Progression in Nasopharyngeal

  2026-07-04

  This study elucidates how Epstein-Barr virus latent membrane protein 2A (LMP2A) activates GCNT3 expression via the mTORC1 pathway in nasopharyngeal carcinoma (NPC) cells. It identifies a positive feedback loop between mTORC1 and GCNT3 that promotes cell proliferation, migration, and epithelial-mesenchymal transition, uncovering a novel regulatory mechanism and potential therapeutic target in NPC.

• Salvianolic Acid B: Advanced Mechanistic and Translational I

  2026-07-03

  Explore the unique molecular mechanisms of Salvianolic acid B in pulmonary fibrosis research. This article delivers advanced scientific analysis and practical assay guidance for Dan Shen Suan B, offering differentiated insights beyond existing content.

10351 records 1/691 page Next 12345 下5页 Last page